Last reviewed · How we verify

NCT02616185

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Terminated Phase 1 Results posted Last updated 2 November 2023
What this trial tests

Phase 1 trial testing PF-06755992 in Prostatic Neoplasms in 91 participants. Terminated before completion.

Timeline
30 December 2015
Primary endpoint
23 February 2021
23 February 2021

Quick facts

Lead sponsorPfizer
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposetreatment
Enrollment91
Start date30 December 2015
Primary completion23 February 2021
Estimated completion23 February 2021
Sites19 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Pfizer — full company profile →

Who can join

18 and older, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Primary · Baseline up to 6 months after End of Treatment (EOT; 52 months in maximum)

An AE was any untoward medical occurrence in a clinical investigation where participant administered a product; the event did not need to have a causal relationship with the treatment. A SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs.

Number of participants with all-causality AEs
GroupValue95% CI
Cohort All mCRPC Patients55
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg20
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg15
Cohort 7A and 3B Combined32
Number of participants with treatment-related AEs
GroupValue95% CI
Cohort All mCRPC Patients51
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg19
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg15
Cohort 7A and 3B Combined31
Number of participants with all-causality SAEs
GroupValue95% CI
Cohort All mCRPC Patients16
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg2
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg6
Cohort 7A and 3B Combined11
Number of participants with treatment-related SAEs
GroupValue95% CI
Cohort All mCRPC Patients11
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg6
Cohort 7A and 3B Combined9
Number of Participants With AEs as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03) (Grade >= 3) Primary · Baseline up to 6 months after EOT (52 months in maximum)

An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. Grades of AEs were defined by NCI CTCAE v 4.03. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL); Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indica

Grade 3 or Grade 4 (all-causality)
GroupValue95% CI
Cohort All mCRPC Patients33
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg10
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg11
Cohort 7A and 3B Combined21
Grade 3 or Grade 4 (treatment-related)
GroupValue95% CI
Cohort All mCRPC Patients23
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg6
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg10
Cohort 7A and 3B Combined17
Grade 5 (all-causality)
GroupValue95% CI
Cohort All mCRPC Patients4
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg1
Cohort 7A and 3B Combined3
Grade 5 (treatment-related)
GroupValue95% CI
Cohort All mCRPC Patients1
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg1
Cohort 7A and 3B Combined0
Number of Participants With AEs Leading to Discontinuation or Dose Reduction Primary · Baseline up to 6 months after EOT (52 months in maximum)

An AE was any untoward medical occurrence in a clinical investigation where participant administered a product; the event did not need to have a causal relationship with the treatment.

Number of participants with permanent discontinuations
GroupValue95% CI
Cohort All mCRPC Patients16
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg1
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg10
Cohort 7A and 3B Combined11
Number of participants with temporary discontinuations
GroupValue95% CI
Cohort All mCRPC Patients17
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg5
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg5
Cohort 7A and 3B Combined9
Number of participants with dose reductions
GroupValue95% CI
Cohort All mCRPC Patients0
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg1
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Number of Participants With Dose-Limiting Toxicities (DLTs) Primary · The first 28 days following the first AdC68 vaccination (on Cycle 1 Day 1)

The following AEs occurring in the first 28 days following the first AdC68 vaccination and not related to disease/progression were DLTs: (a) hematologic (Cohorts 1A to 3A and Cohorts 6A to 9A): Grade 3 neutropenia lasting \>7 days, febrile neutropenia, Grade \>=3 neutropenic infection, Grade \>=3 thrombocytopenia, Grade \>=3 anemia lasting \>7 days, Grade \>=3 lymphopenia lasting \>14 days; (b) non-hematologic (all cohorts): Grade \>=3 laboratory abnormalities either associated with symptoms or associated with worsening of an existing condition or that suggested a new disease process or that r

GroupValue95% CI
Cohort All mCRPC Patients1
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Number of Participants With Laboratory Abnormalities in Hematology (Grade 3 or 4) Secondary · Baseline up to 6 months after EOT (52 months in maximum)

Laboratory abnormalities were graded per NCI CTCAE version 4.03 (Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Hematology parameters included hemoglobin, platelets, white blood cell count, neutrophils, eosinophils, monocytes, basophils and lymphocytes.

Anemia
GroupValue95% CI
Cohort All mCRPC Patients2
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined2
Hemoglobin increased
GroupValue95% CI
Cohort All mCRPC Patients0
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Lymphocyte count increased
GroupValue95% CI
Cohort All mCRPC Patients0
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Lymphopenia
GroupValue95% CI
Cohort All mCRPC Patients7
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg2
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg2
Cohort 7A and 3B Combined4
Neutrophils (absolute)
GroupValue95% CI
Cohort All mCRPC Patients1
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined1
Platelets
GroupValue95% CI
Cohort All mCRPC Patients0
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
White blood cells
GroupValue95% CI
Cohort All mCRPC Patients1
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined1
Number of Participants With Laboratory Abnormalities in Chemistry (Grade 3 or 4) Secondary · Baseline up to 6 months after EOT (52 months in maximum)

Laboratory abnormalities were graded per NCI CTCAE version 4.03 (Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Chemistry parameters included aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen (or urea), creatinine, uric acid, glucose, albumin, phosphorous or phosphate, lactate dehydrogenase, lipase, bicarbonate or carbon dioxide, total protein, TSH (if abnormal, reflex free T4

Alanine aminotransferase
GroupValue95% CI
Cohort All mCRPC Patients1
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg1
Cohort 7A and 3B Combined0
Alkaline phosphatase
GroupValue95% CI
Cohort All mCRPC Patients0
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Amylase
GroupValue95% CI
Cohort All mCRPC Patients2
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Aspartate aminotransferase
GroupValue95% CI
Cohort All mCRPC Patients1
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg1
Cohort 7A and 3B Combined0
Bilirubin (total)
GroupValue95% CI
Cohort All mCRPC Patients0
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg1
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Creatinine
GroupValue95% CI
Cohort All mCRPC Patients1
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Hypercalcemia
GroupValue95% CI
Cohort All mCRPC Patients0
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Hyperglycemia
GroupValue95% CI
Cohort All mCRPC Patients4
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined2
Number of Participants With Laboratory Abnormalities in Urinalysis (Grade 3 or 4) Secondary · Baseline up to 6 months after EOT (52 months in maximum)

Laboratory abnormalities were graded per NCI CTCAE version 4.03 (Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated) and those with at least 1 participant are presented here. Urine parameters included urine protein and urine blood.

GroupValue95% CI
Cohort All mCRPC Patients0
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg0
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg0
Cohort 7A and 3B Combined0
Change From Baseline in T Cell Response to Prostate Specific Antigen (PSA) in Part A Secondary · At screening; Cycle 1: at Day 1, Day 15, Day 29, Day 43, Day 71; Cycle 2: at Day 1, Day 29, and Day 99; at the EOT visit, and 2, 4 and 6 months after EOT.

T cell response to PSA was determined by assaying peripheral blood mononuclear cell (PBMC) samples for cellular immune responses against PSA antigens and was determined as the frequency of interferon-gamma (IFN-γ) spot forming cells (SFC)/million PBMCs. Change from baseline at Cycle 1 Day 71 and at Cycle 2 Day 99 are presented here.

Cycle 1 Day 1 Compared With Cycle 1 Day 71
GroupValue95% CI
Cohort 1A: AdC68 4x10^11 VP + pDNA 5 mg2.83± 4.907
Cohort 2A: AdC68 6x10^11 VP + pDNA 5 mg4.17± 7.217
Cohort 3A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg1.70± 3.801
Cohort 6A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mgNA± NA
Cohort 7A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 300 mg24.25± 34.295
Cohort 9A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 40 mg + PF-06801591 130 mgNA± NA
Cycle 2 Day 1 Compared With Cycle 2 Day 99
GroupValue95% CI
Cohort 1A: AdC68 4x10^11 VP + pDNA 5 mgNA± NA
Cohort 2A: AdC68 6x10^11 VP + pDNA 5 mg5.50± 9.526
Cohort 3A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mgNA± NA
Change From Baseline in T Cell Response to Prostate Stem Cell Antigen (PSCA) in Part A Secondary · At screening; Cycle 1: at Day 1, Day 15, Day 29, Day 43, Day 71; Cycle 2: at Day 1, Day 29, and Day 99; at the EOT visit, and 2, 4 and 6 months after EOT.

T cell response to PSCA was determined by assaying PBMC samples for cellular immune responses against PSCA antigens and was determined as the frequency of IFN-γ SFC/million PBMCs. Change from baseline at Cycle 1 Day 71 and at Cycle 2 Day 99 are presented here.

Cycle 1 Day 1 Compared With Cycle 1 Day 71
GroupValue95% CI
Cohort 1A: AdC68 4x10^11 VP + pDNA 5 mgNA± NA
Cohort 2A: AdC68 6x10^11 VP + pDNA 5 mgNA± NA
Cohort 3A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg1.70± 3.801
Cohort 6A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mgNA± NA
Cohort 7A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 300 mgNA± NA
Cohort 9A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 40 mg + PF-06801591 130 mgNA± NA
Cycle 2 Day 1 Compared With Cycle 2 Day 99
GroupValue95% CI
Cohort 1A: AdC68 4x10^11 VP + pDNA 5 mgNA± NA
Cohort 2A: AdC68 6x10^11 VP + pDNA 5 mgNA± NA
Cohort 3A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mgNA± NA
Change From Baseline in T Cell Response to Prostate Specific Membrane Antigen (PSMA) in Part A Secondary · At screening; Cycle 1: at Day 1, Day 15, Day 29, Day 43, Day 71; Cycle 2: at Day 1, Day 29, and Day 99; at the EOT visit, and 2, 4 and 6 months after EOT.

T cell response to PSMA was determined by assaying PBMC samples for cellular immune responses against PSMA antigens and was determined as the frequency of IFN-γ SFC/million PBMCs. Change from baseline at Cycle 1 Day 71 and at Cycle 2 Day 99 are presented here.

Cycle 1 Day 1 Compared With Cycle 1 Day 71
GroupValue95% CI
Cohort 1A: AdC68 4x10^11 VP + pDNA 5 mg5.50± 9.526
Cohort 2A: AdC68 6x10^11 VP + pDNA 5 mg28.00± 48.497
Cohort 3A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg4.30± 12.736
Cohort 6A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mgNA± NA
Cohort 7A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 300 mgNA± NA
Cohort 9A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 40 mg + PF-06801591 130 mgNA± NA
Cycle 2 Day 1 Compared With Cycle 2 Day 99
GroupValue95% CI
Cohort 1A: AdC68 4x10^11 VP + pDNA 5 mgNA± NA
Cohort 2A: AdC68 6x10^11 VP + pDNA 5 mg36.00± 62.354
Cohort 3A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mgNA± NA
Maximum Observed Plasma Concentration (Cmax) of Tremelimumab in Part A Secondary · Cycle 1: at Day 1 pre-dose, any time between 48 to 120 hr, approximately 168 hr, 336 hr, and 504 hr, at pre-dose on Day 29, Day 57, and Day 85; Cycle 2: at pre-dose on Day 1 and Day 29; at EOT visit, and 2, 4 and 6 months after EOT.

Cmax was defined as the maximum observed plasma concentration. Blood samples (approximately 3 mL whole blood) to provide at least 1 mL of serum for measurement of tremelimumab PK analysis were collected.

GroupValue95% CI
Cohort 3A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg4360± 31
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tremelimumab in Part A Secondary · Cycle 1: at Day 1 pre-dose, any time between 48 to 120 hr, approximately 168 hr, 336 hr, and 504 hr, at pre-dose on Day 29, Day 57, and Day 85; Cycle 2: at pre-dose on Day 1 and Day 29; at EOT visit, and 2, 4 and 6 months after EOT.

Tmax was defined as the time to reach maximum observed plasma concentration. Blood samples (approximately 3 mL whole blood) to provide at least 1 mL of serum for measurement of tremelimumab PK analysis were collected.

GroupValue95% CI
Cohort 3A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg307165 – 477

Adverse events — posted to ClinicalTrials.gov

Time frame: Baseline up to 6 months after EOT (52 months in maximum). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Cohort 1A: AdC68 4x10^11 VP + pDNA 5 mg
Serious: 0/3 (0%)
Deaths: 0/3
Cohort 2A: AdC68 6x10^11 VP + pDNA 5 mg
Serious: 0/4 (0%)
Deaths: 0/4
Cohort 3A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg
Serious: 2/6 (33%)
Deaths: 0/6
Cohort 6A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg
Serious: 2/8 (25%)
Deaths: 1/8
Cohort 7A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 300 mg
Serious: 4/14 (29%)
Deaths: 2/14
Cohort 9A: AdC68 6x10^11 VP + pDNA 5 mg + Treme 40 mg + PF-06801591 130 mg
Serious: 1/3 (33%)
Deaths: 0/3
Cohort 1B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg
Serious: 2/20 (10%)
Deaths: 0/20
Cohort 3B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 300 mg
Serious: 7/18 (39%)
Deaths: 2/18
Cohort 5B: AdC68 6x10^11 VP + pDNA 5 mg + Treme 80 mg + PF-06801591 130 mg
Serious: 6/15 (40%)
Deaths: 1/15

Serious adverse events (48 terms)

ReactionSystemCohort 1A: AdC68 4x10^11 V…Cohort 2A: AdC68 6x10^11 V…Cohort 3A: AdC68 6x10^11 V…Cohort 6A: AdC68 6x10^11 V…Cohort 7A: AdC68 6x10^11 V…Cohort 9A: AdC68 6x10^11 V…Cohort 1B: AdC68 6x10^11 V…Cohort 3B: AdC68 6x10^11 V…Cohort 5B: AdC68 6x10^11 V…
DiarrhoeaGastrointestinal disorders
Abdominal painGastrointestinal disorders
HyponatraemiaMetabolism and nutrition disorders
Arthritis bacterialInfections and infestations
Bladder neck obstructionRenal and urinary disorders
HaematuriaRenal and urinary disorders
HydronephrosisRenal and urinary disorders
Urinary retentionRenal and urinary disorders
Urinary tract obstructionRenal and urinary disorders
ColitisGastrointestinal disorders
Urinary tract infectionInfections and infestations
HyperglycaemiaMetabolism and nutrition disorders
HypocalcaemiaMetabolism and nutrition disorders
HypokalaemiaMetabolism and nutrition disorders
HypomagnesaemiaMetabolism and nutrition disorders
Muscular weaknessMusculoskeletal and connective tissue disorders
MyositisMusculoskeletal and connective tissue disorders
Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)
Cerebrovascular accidentNervous system disorders
Myasthenia gravisNervous system disorders
Acute kidney injuryRenal and urinary disorders
Pulmonary embolismRespiratory, thoracic and mediastinal disorders
HypotensionVascular disorders
Blood loss anaemiaBlood and lymphatic system disorders
Femur fractureInjury, poisoning and procedural complications
Other adverse events (258 terms — click to expand)

ReactionSystemCohort 1A: AdC68 4x10^11 V…Cohort 2A: AdC68 6x10^11 V…Cohort 3A: AdC68 6x10^11 V…Cohort 6A: AdC68 6x10^11 V…Cohort 7A: AdC68 6x10^11 V…Cohort 9A: AdC68 6x10^11 V…Cohort 1B: AdC68 6x10^11 V…Cohort 3B: AdC68 6x10^11 V…Cohort 5B: AdC68 6x10^11 V…
AnaemiaBlood and lymphatic system disorders
FatigueGeneral disorders
Influenza like illnessGeneral disorders
DiarrhoeaGastrointestinal disorders
ArthralgiaMusculoskeletal and connective tissue disorders
HyponatraemiaMetabolism and nutrition disorders
Aspartate aminotransferase increasedInvestigations
Platelet count decreasedInvestigations
HypoalbuminaemiaMetabolism and nutrition disorders
HypocalcaemiaMetabolism and nutrition disorders
ConstipationGastrointestinal disorders
Amylase increasedInvestigations
Lipase increasedInvestigations
Decreased appetiteMetabolism and nutrition disorders
HeadacheNervous system disorders
HaematuriaRenal and urinary disorders
PruritusSkin and subcutaneous tissue disorders
Injection site painGeneral disorders
Lymphocyte count decreasedInvestigations
NauseaGastrointestinal disorders
ChillsGeneral disorders
Alanine aminotransferase increasedInvestigations
Back painMusculoskeletal and connective tissue disorders
MyalgiaMusculoskeletal and connective tissue disorders
Pain in extremityMusculoskeletal and connective tissue disorders
Activated partial thromboplastin time prolongedInvestigations
HypophosphataemiaMetabolism and nutrition disorders
Blood alkaline phosphatase increasedInvestigations
International normalised ratio increasedInvestigations
VomitingGastrointestinal disorders
PyrexiaGeneral disorders
FallInjury, poisoning and procedural complications
Blood creatinine increasedInvestigations
Weight decreasedInvestigations
HypokalaemiaMetabolism and nutrition disorders
DizzinessNervous system disorders
CoughRespiratory, thoracic and mediastinal disorders
InsomniaPsychiatric disorders
HypotensionVascular disorders
HyperthyroidismEndocrine disorders

Most-reported serious reactions: Diarrhoea, Abdominal pain, Hyponatraemia, Arthritis bacterial, Bladder neck obstruction, Haematuria, Hydronephrosis, Urinary retention.

Data from ClinicalTrials.gov NCT02616185 adverse events section.

Sponsor's own description

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
    Fukumura D, Kloepper J, Amoozgar Z, Duda DG, et al · · 2018 · cited 1560× · PMID 29508855 · DOI 10.1038/nrclinonc.2018.29
  2. Turning the corner on therapeutic cancer vaccines.
    Hollingsworth RE, Jansen K. · · 2019 · cited 486× · PMID 30774998 · DOI 10.1038/s41541-019-0103-y
  3. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses.
    Vermaelen K. · · 2019 · cited 139× · PMID 30723469 · DOI 10.3389/fimmu.2019.00008
  4. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
    Mougel A, Terme M, Tanchot C. · · 2019 · cited 108× · PMID 30923527 · DOI 10.3389/fimmu.2019.00467
  5. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
    Gatti-Mays ME, Redman JM, Collins JM, Bilusic M. · · 2017 · cited 82× · PMID 28857666 · DOI 10.1080/21645515.2017.1364322
  6. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
    Li SJ, Chen JX, Sun ZJ. · · 2021 · cited 63× · PMID 34137513 · DOI 10.1002/cac2.12183
  7. Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.
    Tay BQ, Wright Q, Ladwa R, Perry C, et al · · 2021 · cited 42× · PMID 34065557 · DOI 10.3390/vaccines9050535
  8. Cancer vaccines: translation from mice to human clinical trials.
    Maeng H, Terabe M, Berzofsky JA. · · 2018 · cited 40× · PMID 29554495 · DOI 10.1016/j.coi.2018.03.001

Verify or expand the search:

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

Other Pfizer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02616185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing